— Know what they know.
Not Investment Advice
MXCT.L (LSE) is a cross-listing of MXCT (NASDAQ). Showing primary listing data.

MXCT

MaxCyte, Inc.
1W: -5.7% 1M: -12.7% 3M: -57.7% YTD: -55.5% 1Y: -78.1% 3Y: -83.5%
$0.69
-0.05 (-6.81%)
After Hours: $0.73 (+0.04, +6.53%)
NASDAQ · Healthcare · Medical - Devices · $73.6M · Alpha Radar Neutral · Power 40
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$73.6M
52W Range0.643-3.17
Volume1,949,609
Avg Volume1,063,406
Beta1.43
Dividend
Analyst Ratings
4 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOMaher Masoud
Employees114
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-07-30
9713 Key West Avenue
Rockville, MD 20850
US
301 944 1700
About MaxCyte, Inc.

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Recent Insider Trades

NameTypeSharesPriceDate
Swirsky Douglas J S-Sale 10,142 $0.81 2026-03-17
Swirsky Douglas J P-Purchase 50,000 $1.29 2025-08-13
Masoud Maher P-Purchase 75,000 $1.37 2025-08-13
Erck Stanley C P-Purchase 100,000 $1.37 2025-08-13
DOUGLAS RICHARD P-Purchase 80,000 $1.39 2025-08-13

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms